Literature DB >> 22019046

Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor.

Noriyasu Kato1, Mitsuru Oka, Takayo Murase, Masahiro Yoshida, Masao Sakairi, Satoko Yamashita, Yoshika Yasuda, Aya Yoshikawa, Yuuji Hayashi, Mitsuhiro Makino, Motohiro Takeda, Yakufu Mirensha, Takuji Kakigami.   

Abstract

In the course of our program for discovery of novel DPP-IV inhibitors, a series of pyrazolo[1,5-a]pyrimidines were found to be novel DPP-IV inhibitors. We identified N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (4a) and described its pharmacological profiles.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22019046     DOI: 10.1016/j.bmc.2011.09.043

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

1.  Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs.

Authors:  Shinji Furuta; Miyuki Tamura; Hiroko Hirooka; Yukie Mizuno; Mika Miyoshi; Yoshiyuki Furuta
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-02-23       Impact factor: 2.441

2.  Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.

Authors:  Miyako Kishimoto; Mitsuhiko Noda
Journal:  Clin Drug Investig       Date:  2015-02       Impact factor: 2.859

3.  Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor.

Authors:  Hiroyuki Nojima; Kazuhiko Kanou; Genki Terashi; Mayuko Takeda-Shitaka; Gaku Inoue; Koichiro Atsuda; Chihiro Itoh; Chie Iguchi; Hajime Matsubara
Journal:  BMC Struct Biol       Date:  2016-08-05

4.  Exploration of nitrogen heterocycle scaffolds for the development of potent human neutrophil elastase inhibitors.

Authors:  Niccolò Cantini; Andrei I Khlebnikov; Letizia Crocetti; Igor A Schepetkin; Giuseppe Floresta; Gabriella Guerrini; Claudia Vergelli; Gianluca Bartolucci; Mark T Quinn; Maria Paola Giovannoni
Journal:  Bioorg Med Chem       Date:  2020-11-06       Impact factor: 3.641

5.  Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors.

Authors:  Yoshinobu Nakamaru; Fumihiko Akahoshi; Hiroaki Iijima; Noriko Hisanaga; Toshiyuki Kume
Journal:  Biopharm Drug Dispos       Date:  2016-01-08       Impact factor: 1.627

Review 6.  New directions for protease inhibitors directed drug discovery.

Authors:  Yoshio Hamada; Yoshiaki Kiso
Journal:  Biopolymers       Date:  2016-11-04       Impact factor: 2.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.